Sensing of mycobacterial arabinogalactan by galectin-9 exacerbates mycobacterial infection
- EMBO Rep. 2021 Jul 5;22(7):e51678. doi: 10.15252/embr.202051678.
- 1. Shanghai Key Lab of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- 2. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- 3. State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai, China.
- 4. Department of Microbiology, Key Laboratory for Tropical Diseases Control of the Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- 5. Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- 6. Department of TB, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- 7. Key Laboratory of Medical Molecular Virology of the Ministry of Education/Ministry of Health, School of Basic Medical Sciences, Fudan University, Shanghai, China.
- 8. Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany.
- 9. Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
- 10. Institute of Immunology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany.
- 11. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- 12. Clinical and Translational Research Center of Shanghai First Maternity and Infant Hospital, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China.
- 13. Division of Protein and Nucleic Acid Chemistry, MRC Laboratory of Molecular Biology, Cambridge, UK.
- 14. Hagler Institute for Advanced Study at Texas A&M University, College Station, TX, USA.
- 15. Max Planck Institute for Biophysical Chemistry, Göttingen, Germany.
- 16. Clinical and Translational Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- 17. Central Laboratory, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Mycobacterial arabinogalactan (AG) is an essential cell wall component of mycobacteria and a frequent structural and bio-synthetical target for anti-tuberculosis (TB) drug development. Here, we report that mycobacterial AG is recognized by Galectin-9 and exacerbates mycobacterial Infection. Administration of AG-specific Aptamers inhibits cellular infiltration caused by Mycobacterium tuberculosis (Mtb) or Mycobacterium bovis BCG, and moderately increases survival of Mtb-infected mice or Mycobacterium marinum-infected zebrafish. AG interacts with carbohydrate recognition domain (CRD) 2 of Galectin-9 with high affinity, and Galectin-9 associates with transforming growth factor β-activated kinase 1 (TAK1) via CRD2 to trigger subsequent activation of extracellular signal-regulated kinase (ERK) as well as induction of the expression of Matrix Metalloproteinases (MMPs). Moreover, deletion of Galectin-9 or inhibition of MMPs blocks AG-induced pathological impairments in the lung, and the AG-galectin-9 axis aggravates the process of Mtb Infection in mice. These results demonstrate that AG is an important virulence factor of mycobacteria and Galectin-9 is a novel receptor for Mtb and Other mycobacteria, paving the way for the development of novel effective TB immune modulators.